Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Certolizumab pegol demonstrates positive results in two Phase III Crohn’™s disease trials

28.07.2005


UCB today announced positive results for the two pivotal Phase III trials (PRECISE 1 and 2) of certolizumab pegol (CDP870) in the induction and maintenance of clinical response in moderate to severe active Crohn’TMs disease. The PRECiSE trials assessed the safety and efficacy of CIMZIATM compared to placebo over a 26 week period, in a total of 1330 patients with active Crohn’TMs disease.

Data from PRECiSE 1 and 2 will be presented in more detail at the major forthcoming gastroenterology medical congresses.

About Crohn’TMs Disease

Crohn’TMs disease is a chronic inflammatory disease of the gastrointestinal tract with the disease typically localized in the terminal part of the ileum (a portion of the small intestine) and right colon (a portion of the large intestine). Crohn’TMs disease affects almost 1 million patients worldwide, with the disease typically appearing early in life. Crohn’TMs disease is characterized by a variety of symptoms, although different in every individual, and may include persistent diarrhea, abdominal pain, and at times loss of appetite/weight, fever or rectal bleeding . Unfortunately there is no single test to diagnose Crohn’TMs disease and because it can often imitate other gastroenterological conditions, patients may experience a lengthy diagnosis process. Although Crohn’TMs disease affects males and females equally of all ages, the most affected in the U.S. are 20-29 year olds and 30-39 year olds . The disease also occurs in young children and adults over 70 years of age. In addition, American Jews of European backgrounds are more likely than the general population to develop Crohn’TMs disease.

Crohn’s Disease - United States (Prevalence)

Yrs of age 2005 %
0-9 30906 8%
10-19 32491 9
20-29 145598 39%
30-39 68205 18%
40-49 23525 6%
50-59 41850 11%
60-69 11669 3%
70-79 11656 3%
80+ 7131 2%


About CIMZIATM

CIMZIATM is a PEGylated Fab’TM fragment of a humanized anti-TNF alpha monoclonal antibody, with high affinity for both soluble and membrane-bound TNF alpha. CIMZIATM is also currently the subject of Phase III clinical trials in rheumatoid arthritis.

About UCB

UCB (www.ucb-group.com) is a global biopharmaceutical leader dedicated to the research, development and commercialization of innovative products in the fields of central nervous system disorders, allergy and respiratory diseases, immune and inflammatory disorders and oncology. UCB employs over 8,500 people operating in over 40 countries. UCB is listed on the Euronext Brussels with a market capitalization of approximately € 5.8 billion. Worldwide headquarters are located in Brussels, Belgium.

UCB Pharma, Inc. is the North American subsidiary of UCB, with U.S. headquarters located in Smyrna, Georgia. UCB’TMs key products in the U.S. are Keppra® (levetiracetam), Zyrtec®’ (cetirizine HCl), Tussionex® CIII (hydrocodone polistirex/chlorpheniramine polistirex), and Metadate® CD CII (methylphenidate HCl, USP).

’ Zyrtec is licensed to and co-promoted with Pfizer, Inc. in the United States.

Lisa Garman | EurekAlert!
Further information:
http://www.ucb-group.com

More articles from Medical Engineering:

nachricht Surgery involving ultrasound energy found to treat high blood pressure
24.05.2018 | Queen Mary University of London

nachricht XXL computed tomography: a new dimension in X-ray analysis
17.05.2018 | Fraunhofer-Gesellschaft

All articles from Medical Engineering >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Powerful IT security for the car of the future – research alliance develops new approaches

The more electronics steer, accelerate and brake cars, the more important it is to protect them against cyber-attacks. That is why 15 partners from industry and academia will work together over the next three years on new approaches to IT security in self-driving cars. The joint project goes by the name Security For Connected, Autonomous Cars (SecForCARs) and has funding of €7.2 million from the German Federal Ministry of Education and Research. Infineon is leading the project.

Vehicles already offer diverse communication interfaces and more and more automated functions, such as distance and lane-keeping assist systems. At the same...

Im Focus: Molecular switch will facilitate the development of pioneering electro-optical devices

A research team led by physicists at the Technical University of Munich (TUM) has developed molecular nanoswitches that can be toggled between two structurally different states using an applied voltage. They can serve as the basis for a pioneering class of devices that could replace silicon-based components with organic molecules.

The development of new electronic technologies drives the incessant reduction of functional component sizes. In the context of an international collaborative...

Im Focus: LZH showcases laser material processing of tomorrow at the LASYS 2018

At the LASYS 2018, from June 5th to 7th, the Laser Zentrum Hannover e.V. (LZH) will be showcasing processes for the laser material processing of tomorrow in hall 4 at stand 4E75. With blown bomb shells the LZH will present first results of a research project on civil security.

At this year's LASYS, the LZH will exhibit light-based processes such as cutting, welding, ablation and structuring as well as additive manufacturing for...

Im Focus: Self-illuminating pixels for a new display generation

There are videos on the internet that can make one marvel at technology. For example, a smartphone is casually bent around the arm or a thin-film display is rolled in all directions and with almost every diameter. From the user's point of view, this looks fantastic. From a professional point of view, however, the question arises: Is that already possible?

At Display Week 2018, scientists from the Fraunhofer Institute for Applied Polymer Research IAP will be demonstrating today’s technological possibilities and...

Im Focus: Explanation for puzzling quantum oscillations has been found

So-called quantum many-body scars allow quantum systems to stay out of equilibrium much longer, explaining experiment | Study published in Nature Physics

Recently, researchers from Harvard and MIT succeeded in trapping a record 53 atoms and individually controlling their quantum state, realizing what is called a...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

In focus: Climate adapted plants

25.05.2018 | Event News

Save the date: Forum European Neuroscience – 07-11 July 2018 in Berlin, Germany

02.05.2018 | Event News

Invitation to the upcoming "Current Topics in Bioinformatics: Big Data in Genomics and Medicine"

13.04.2018 | Event News

 
Latest News

In focus: Climate adapted plants

25.05.2018 | Event News

Flow probes from the 3D printer

25.05.2018 | Machine Engineering

Less is more? Gene switch for healthy aging found

25.05.2018 | Life Sciences

VideoLinks
Science & Research
Overview of more VideoLinks >>>